Moreover, it was demonstrated that inhibiting the transduction of IL-6 signals in a therapy by tocilizumab decreased the production of plasminogen activator inhibitor-1 and resolves clinical manifestations in acute form of COVID-19. This evidence concerns the gene IL6 and COVID-19.